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A positive surgical margin at prostatectomy is deﬁned as tumor cells touching the inked edge of the specimen. This ﬁnding is
reported in8.8%to42%ofcases(medianabout20%)invariousstudies.Itisoneofthemaindeterminantsofeventualbiochemical
(PSA) failure, generally associated with a doubled or tripled risk of failure. The eﬀect of a positive margin on outcome can be
modiﬁed by stageorgrade andthe length,number andlocationofpositivemargins,as well as by technical operative approach and
duration of operator experience. This paper tabulates data from the past decade of studies on margin status.
1.Introduction
1.1. Deﬁnition of a Positive Surgical Margin (PSM) in Radical
Prostatectomy Specimens. A sw i t ha l ls u r g i c a ls p e c i m e n s
resected for cancer, the margins of a prostatectomy specimen
are inked, usually using one color dye for the right side
and one for the left. It is the pathologist’s task to assess the
microscopic slides and determine the proximity of tumor
glands or cells to the ink to decide whether there is a deﬁnite
positive surgical margin (PSM) (Figure 1).
A fundamental question is whether a tumor focus that is
close to, but not touching, the resection margin (Figure 2)
holds the same implications as a PSM. This question was
ﬁrst answered by Epstein and Sauvageot in 1997, in a study
of 101 cases [1]. They found that patients with biochemical
progression were no more likely to have tumor close to
the margin than those without progression. Emerson et al.,
conﬁning their study to just 278 margin-negative whole-
mount prostate cases, validated that the closest distance
between tumor and resection margin was not a signiﬁcant
predictor of PSA recurrence by univariate or multivariate
analysis [2]. Thus, it was the consensus of the International
Society of Urological Pathology in 2009 not to mention
in written reports if tumor merely approaches but does
not touch the margin [3]. This contrasts with the practice
in other types of specimens such as breast lumpectomy
specimens, in which the distance of tumor close to the
margin is reported and does matter for outcome.
A PSM is a strong determinant of the probability of bio-
chemical failure and is at least as important as grade, stage,
and preoperative serum prostate-speciﬁc antigen (PSA). In
unselected contemporary studies the PSM rate ranges from
8.8% [4] to 37% [5]. The interobserver reproducibility of
designation of a PSM by urologic pathologists, using the
deﬁnition of tumor on ink, has been shown to be good
to excellent. The kappa value is 0.73 for deﬁnitive surgical
margin status [6]. This supports the validity of many studies
in concluding that, compared to negative surgical margin
(NSM) status, a PSM correlates with a signiﬁcant rise in
biochemical failure rate. The purpose of this paper is to
provide a compendium for urologists and their patients of
all that is known about prostate margin status as an outcome
predictor.
2.Methods
A review of papers pertaining to prostate margin status and
itseﬀectonoutcomewasundertakenusing PubMedsearches
from 1997 to the present.2 Prostate Cancer
Table 1: Comparisonof PSM rates by technical approach.
First author,
yr No. of pts Cohort
years
Median
f/u, yr
Open Laparoscopic Robotic Failure
rate if PSM PSM rate P value PSM rate HR, P val. PSM rate HR, P val.
Williams
2010 [7] 4240 2004–
2006 20.1% 17.4% 17.4%
Coelho
2010 [8]
≥250†† 1994–
2009 24.0% 21.3% 13.6%
Sciarra
2010 [9] 200 2003–
2007
18%
anterograde,
14%
retrograde
P = .03 — — —
Williams
2010 [10] 950 2005–
2008 7.6% 13.5%, HR 1.9∗,
P = .007 ——
Coelho
2010 [11] 876 2008-
2009 —— pT2, 6.8%,
pT3, 34.0% P<. 0001 —
Guru
2009 [12] 480 2005–
2008 ——
5% apical,
2% versus
8%∗∗
—
Bong
2009 [13] 301 1994–
2006 2.0
24.7% at 1
institution
but 4.2% at
another
P<. 01∗∗∗ ——
25.6% at 1
institution
but 100%
at other
Hakimi
2009 [14] 150 2001–
2008 13.7% 12%
6.7%
versus
5.3%
P = .37
Laurila
2009 [15] 192 2006 14% — 13%
P = .5, no
diﬀ in
apical
margin
—
Terakawa
2008 [16] 137 2000–
2007 PSM Not signif. —
More
multiple
PSM, get #
—
Smith
2007 [17] 400 2002–
2006 35%† — 15% P<. 001 —
Silva
2007 [18] 179 1999–
2003 41.6% — 24.44% P = .023 —
Touijer
2007 [19] 1177 2003–
2005
11.0%;
pT2 5.3%,
pT3 22.0%
11.3%;
pT2 8.2%;
pT3 17.2%
HR 1.2,
P = .5 ——
∗OR falls to 1.6 if nerve-sparing is eliminated as a variable (P = .05).
∗∗Lower rate achieved by cold incision of the dorsal venous complex before suture ligation.
∗∗∗For the same surgeon; but higher average pathologic stage at the ﬁrst institution.
†But open method was used for more high-risk cases and also cases witha higher preoperative PSA, P = .002.
††Review of several papers.
3.Results
3.1. Can Prostate Biopsy Results Predict Margin Status? We
undertook a study a few years ago to determine the extent
to which prostate biopsy results could predict cancer at
prostatectomy that is unifocal, unilateral, margin-negative,
and of small volume [20]. These four factors are the main
criteria for choosing minimally invasive therapies such as
targeted focal ablation of the prostate, as alternatives to
radical prostatectomy. Unilateral cancer at prostatectomy
was predicted by unilateral cancer in the biopsy (OR,
4.30) and unifocal cancer in the biopsy (OR, 2.63). In
that study, negative surgical margins were predicted by
unilateral cancer in the biopsy (OR 2.53, positive predictive
value 82%). Therefore, biopsy ﬁndings can strongly predict
prostatectomy margin status and other ﬁndings.
3.2. Comparison of PSM Rates by Technical Approach
(Table 1). In the past decade, nonrobotic or robotic laparo-
scopic techniques have been increasingly used in place of
conventional open radical prostatectomy. The laparoscopic
approaches are often considered superior for continence and
potency [8, 11, 12, 14, 16]. Most studies involving prostateProstate Cancer 3
Table 2: Comparisonof PSM rates by duration of surgical experience.
First author, yr Number of cases Cohort years
PSM rate
Open Laparoscopic Robotic
Rodriguez 2010 [21] 400, by intervals of 100 2004–2006 —
For pT2:
28.4%–31.9% to
11.6%–11.5%∗
—
Yee 2009 [22] 50, then 250 2005–2008 — —
Cases 1–50: 36%,
51–250: 17.6%,
251–450: 7.5%
Liss 2008 [23] 216 2003–2007 — —
14.8%, decr. over
time P = .03,
nerve-sparing
increased risk
P = .03
Eastham 2007 [24] 2442
1983–1990
and
1991–2004
18% versus 10%,
P = .001 ——
Touijer 2007 [19] 1177 2003–2005 No decrease over
time
Decreased over
time, P = .0002 —
∗First 200 cases versus last 200 cases.
Table 3: The eﬀect of margin status on PSA failure rate at 10 years.
First author, yr n Cohort years PSA fail
criterion, ng/mL %P S M ,o v e r a l l
% biochemical failure rate
PSM NSM P value, HR
Williams 2011 [25] 158†† 2005–2009 — 13 No f/u
Ahyai 2010 [26] 932 1992–2004 ≥0.1 12.9 21.7 6.9 P = .001
Tsao 2009 [27] 100∗ 2004–2007 ≥0.2 23 —
Sæther 2008 [28] 219 1996–2004 ≥0.2 32.4 40 18 P = .017
Pﬁtzenmaier 2008 [29] 406 1990–2006 ≥0.2 17.2 64.3 20.5 P<. 001, HR 3.21
Swanson 2007 [30] 719 1985–1995 ≥0.3 15.3 63 27 P<. 0001
Ahyai 2010 [26] 936 1992–2003 ≥0.4 37 19 7 P<. 01
Kausik 2002 [31] 1202† 1987–1995 >0.2 42 35 24 P = .0001
Menon 2010 [32] 1384 2001–2005∗ ≥0.2 25.1 — — P<. 0001, HR
2.43 (1.72–3.42)
∗Robotic only.
†pT3 cases only.
††pT2 cases only.
pathology after laparoscopic approaches have found a PSM
rate comparable with that of an open approach [7, 8, 14,
15, 19]. PSM rates were as follow: open, 7.6% [10] to 41.6%
[18]; laparoscopic without robot, 11.3% [19] to 21.3% [8];
robotic, 13% [15] to 24.44% [18].
PSM rate for robotic approaches was found to be signiﬁ-
cantly worse than that for open ones (P = .007) in one study
[10]; however, two other studies found open approaches
superior to the robotic ones [17, 18]. In the study that found
theopenapproachbetter,theresultwasconfoundedbynerve
sparing, so robotic prostatectomies showed a nonsigniﬁcant
trend toward lower PSM for a non-nerve-sparing approach
(P = .09) [10]. When the anterograde open approach was
compared with the retrograde approach, signiﬁcantly fewer
PSMs were found by retrograde approach (P = .03) [9].
In a comparison of robotic versus nonrobotic laparo-
scopic approaches, one study found the robotic method
superior [8]. Another found that the outcome was highly
stage dependent, with 7% of pT2 patients with biochemical
failure as opposed to 34% of pT3 patients [11]. Failure
could also depend on number of positive margins [16]. In
a study evaluating the robotic approach, a lower PSM rate
was achieved by cold incision of the dorsal venous complex
before suture ligation [12].
3.3. Comparison of PSM Rates by Duration of Surgical
Experience (Table 2). In the above comparison of surgical
approaches, it must be noted that the new laparoscopic
approaches have a demonstrable learning curve. That is, in
three studies conducted in the middle of the 2000–2010
decade, the PSM rate improved after a few years of practice
[21–23]. While a signiﬁcant decrease in PSM rate occurred
over time with a laparoscopic approach, PSM held steady
for open procedures during the same time period [19]. Even4 Prostate Cancer
Figure 1: Prostatectomy specimen with a deﬁnite positive surgical
margin (PSM).The inked resection margin transects tumor (400x).
Figure 2: Prostatectomy specimen with negative surgical margin.
Tumorapproacheswithinlessthan1millimeteroftheinkedmargin
(400x).
with the open approach, during the 1990s and early 2000s,
one study had noted that there was also alearning curvewith
respect to the PSM rate [24].
It is a bit disconcerting but it also must be admitted that
individual surgeons may vary in their frequency of PSMs. In
a study of 4,629 men operated on by open prostatectomy by
one of44 surgeons, for the 26surgeons who each treated >10
patients, the rate of PSM ranged from 10% to 48% [33]. A
6-fold diﬀerence was even reported for the same surgeon at
diﬀerent institutions [13].
3.4. Margin Status Eﬀe c to nP S AF a i l u r eR a t ea t1 0Y e a r s
(Table 3). PSM rates in studies not comparing approaches
ranged from 13% [25] to 42% [31] with a median 23% [27].
In the presence of a PSM, the failure rate was either double
[28, 30, 32, 34, 40, 42, 43], triple [5, 26, 29, 38]o rs h o w e d
an increase of greater magnitude [4, 39] compared to NSM.
Two studies did not specify this [5, 30]. In studies reporting
a Hazard Ratio (HR) comparing a PSM to NSM, the HR
ranged from 1.3 [46]u pt o3 . 6 6[ 42].
3.5. Tumor Stage (Table 4)o rG r a d e( Table 5)C a nM o d i f yt h e
Eﬀect of PSM on PSA Failure Rates, at 10 Years. Nine studies
compared PSA failure rates as a function of pathologic stage
pT3a and pT3b versus pT2 or of pT3 versus pT2. (The
apparent stage sometimes cannot be assessed because of
capsular incision [58].) Failure rates with a PSM in stage
pT2 ranged from 10.6% [38] to 63% [42], with an HR of
1.7 [4]t o3 . 8 1[ 34] compared to having an NSM. For stage
pT3a, failure rates were 38% [35] to 58% [36], with HR
ranging from 1.4 [46]t o3 . 6[ 4] compared to NSM. For
stage pT3b, one study reports 71% failure, with HR of 1.4
compared toNSM[35].Somestudieschose to combineboth
pT3 substages and disclosed failure rates from 57% [37]t o
75% [43]a n dH Ro f4 . 1[ 37] to 11.85 [38]. Thus, PSMexerts
an eﬀect that is synergistic with increasing stage, although
the HRcompared to NSM seems fairly constant across stages
pT2, pT3a, and pT3b, at about 3 to 4. A study examining
the phenomenon of capsular incision, sometimes denoted
pT2+, found a 29.3% failure rate versus 7.3% for no incision
(P<. 0001) [46].
T h eH Rf o rf a i l u r ew i t haP S Ms e e m st oi n c r e a s ew i t h
increasing Gleason score [4, 35, 42, 44]. In one study [34],
however, after controlling for Gleason score, a PSM versus
NSM with Gleason ≤7 was signiﬁcantly predictive of failure,
while PSMversus NSMwith Gleason ≥8w a sn o t( P = .115).
Finally, Cao et al. noted that the Gleason score at the positive
margin was predictive of biochemical recurrence [59]. Also,
astheGleasonscoreofthemain tumorrose,theconcordance
with the grade at the margin diminished: 99%for score 6 but
38%forscore9.Bymultivariateanalysis, Gleasonscoreatthe
margin predicted biochemical failure (P<. 05) [59].
3.6. The Eﬀect of PSM on Mortality Rate at 10 Years Is
Also Modiﬁed by Stage and Grade (Table 6). Three studies
addressed the prostate cancer-speciﬁc death rate in the
presence of a PSM. Two studies, one based on the SEER
cancer data registry [45], found a signiﬁcantly higher death
rate at 10 years in the presence of a PSM [34, 45], namely,
0.86% versus 0.33% (P<. 001) and 2.6% versus 0.6% which
was signiﬁcant (P = .006). In another study, from the Mayo
Clinicregistry, a PSMwas nota signiﬁcant predictor ofdeath
among 11,729 cases (P = .15), but did predict death in the
subset that was stage pT3 [34].
3.7. PSA Failure Rates after a PSM Are Inﬂuenced by Length
and Number of PSM (Table 7)a n db yL o c a t i o no fP S M
(Table 8). Many pathologists report the length of a PSM.
Using categorical PSM length cut-oﬀs between 3mm and
10mm, length signiﬁcantly aﬀected outcome in many [36,
41, 47–49, 58]b u tn o ta l l[ 50–52] studies. Emerson et al.
[53] found a PSM length >3mm to be a signiﬁcant outcome
predictorbyunivariateanalysisbutitfellshortofsigniﬁcance
by multivariate analysis (P = .076) [53]. Moreover, the
length of PSM by frozen section predicted residual tumor in
additionally resected neurovascular bundles by multivariate
analysis (P<. 001) [55].
The number of PSMs probably lacks predictive value.
In most studies, number of PSM was not signiﬁcant forProstate Cancer 5
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Table 5: Modiﬁcation of PSA failure rates according to grade, at 10 years (unless speciﬁed).
First author,
yr n Cohort
years
PSA Fail
criterion, ng/mL
%P S M ,
overall
% biochemical failure rate Gleason score eﬀect on failure if PSM
PSM NSM P value, HR Comparisons P value, HR
Ploussard
2010 [34] 1943 2000–
2008 >0.2 25.6 54.2 29.9 P<. 001
HR 2.6
≤7v e r s u s≥8 P<. 001
P = .115
Bud¨ aus
2010 [35] 4490 1992–
2008
≥0.1 18.9 — —
compared to
GS = 6: for 3 + 4,
for 4 + 3, for ≥8,
HR 2.81
HR 6.57 HR 9.86,
all P<. 001
Brimo
2010 [36] 108† 1995–
2008
≥0.2 Inclusion
criterion† —— S c o r e a t m a r g i n P = .007
Alkhateeb
2010 [44] 11,729‡ 1992–
2008
≥0.4 31.1 56 77 P<. 0001
HR 1.63
Low risk 5.1%
versus 0.4%;
med. risk 17%
versus 65%;
hi. risk 43.9%
versus 21.5%
—
Orvieto
2006 [4] 996 1994–
2004
≥0.1
All 8.8;
pT2 1.7,
pT3a 24.9,
pT3b 27.1
35 7.8 P<. 001
HR 3.27 7v e r s u s≥8, P<. 001, HR 7.2
P<. 001, HR 21
Karakiewicz
2005 [42] 5831 1983–
2000
≥0.1 to ≥0.4 26.7 63.9 29.9 P = .001
HR 3.66
≥7 P ≤ .008, HR 2.81
†Restricted to GS = 7, stage pT3a, and PSM.
‡Risk groups based on Gleason score and preoperative PSA: low = PSA < 10, Gleason ≤ 6; medium = PSA 10–20 or Gleason 7; high = PSA > 20 or Gleason
≥ 8.
Table 6: Modiﬁcation of prostate cancer mortality rates according to stage or grade, at 10 years.
First author,
yr n
PSA Fail
criterion,
ng/mL
PSM,
%
Median
f/u, yr
PCa death rate if PSM rate or HR by stage PSM rate by grade
PSM, % NSM, % P value, HR pT2 pT3 a-b Gleason ≥ 7 P value
Wright
2010 [45] 65,633 — 21.2 7 0.86 0.33 P<. 001 17.7% 43.8%,
P<. 001
27.5%
versus
18.3%
P<. 001
Boorjian
2010 [34] 11,729 ≥0.4 31.1 8.2 4 1 P = .15 HR 1.0 HR 2.1,
P<. 0001 ——
Ploussard
2010 [34] 1943 >0.2 25.6 6.7 2.6 0.6
P = .006,
3.7
(1.5–9.5)
16.0 33.6–40.2 — —
outcome [29, 31, 47, 49]. In two studies, multiple PSMs as
opposed to a single PSM predicted failure (HR 1.4, P = .002
by multivariate analysis or HR = 2.19) [54, 58]. In another
study, number of PSMs carried only borderline signiﬁcance
when ≥3 foci were positive compared to one (P = .06) and
not signiﬁcant for 2 foci compared to one [50]. Emerson et
al. found that PSM number predicted failure by univariate
analysis (P = .037) but lost most of its predictive value when
adjusted for Gleason score (P = .076) [53].
ThemostcommonlocationofaPSMwasintheposterior
or posterolateral prostate [41, 47, 49], although one study
found PSM equally common at the apex [24]. A positive
apical soft tissue margin appears more consequential than
a prostatic tissue margin [56]. Eastham et al. noted that
the elevated risk of a posterior PSM means that “eﬀorts
to maintain adequate tissue covering including the routine
excision of Denonvilliers’ fascia and a component of the fat
of the anterior rectal wall should be made in all patients...”
[24]. Broken down by various sites, a posterolateral PSM
predicted failure in most studies [24, 48]b u tn o ta l l[ 49].
Comparing various sites of PSM, the eﬀect of an apical
PSM was not signiﬁcantly diﬀerent from PSM at posterolat-
eral or other sites [29, 52, 58], and another study concluded
that the PSM location seemed not to predict failure [53].
However, in two studies, a positive posterolateral margin
predicted failure while the apical margin did not [24, 57].
Possibly, residual apical tumor is less viable than residual
tumor in the posterolateral region.
4.Conclusion
Prostate margin status is an important determinant of
patient outcome after radical prostatectomy. In a 2010 Col-
legeofAmericanPathologistssurvey,thisfeaturewasmissing
from 1% of pathology reports [60], thus the inclusion of this
and other essential features is a quality assurance concernProstate Cancer 7
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for pathologists. Most urologic pathologists endorse the
reporting of the extensiveness of positive margins, expressed
as length, number, or radial extent positive for tumor
cells; all these measurements have some relevance toward
outcome. The presence of a positive margin confers a 2-
3-fold increased hazard ratio for biochemical recurrence—
modiﬁed by stage and tumor grade—and necessitates close
clinical followup.
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